
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 6 chart positions in 6 markets.
By chart position
- 🇦🇷AR · Medicine#1830K to 100K
- 🇳🇬NG · Medicine#813K to 10K
- 🇨🇭CH · Medicine#893K to 10K
- 🇳🇿NZ · Medicine#913K to 10K
- 🇭🇺HU · Medicine#121500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
12K to 41K🎙 Daily cadence·215 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
40K to 136K🇦🇷74%🇳🇬7%🇨🇭7%+3 more - Active Followers
Loyal subscribers who consistently listen
16K to 54K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 16 epsHosts
Recent guests
Recent episodes
205. ESTRO update with A/Prof Steven David
Jun 14, 2026
Unknown duration
204. Jake Messier on Living with Metastatic Male Breast Cancer
Jun 7, 2026
43m 58s
203. Back to Basics - Early Pancreatic Cancer
May 31, 2026
25m 30s
202. Back to Basics - Advanced Pancreatic Cancer
May 24, 2026
22m 27s
201. Back to Basics - Advanced Gastric/GOJ Cancer
May 17, 2026
28m 21s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/14/26 | ![]() 205. ESTRO update with A/Prof Steven David | This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer radiation space, including hyperfractionation of treatment, the utilisation of AI for radiation planning (Archery Trial), and the DBCG RT Natural Trial, which examined whether omitting partial breast irradiation (PBI) after breast-conserving surgery was safe in those over 60 (spoiler: you should still give PBI).For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 6/7/26 | ![]() 204. Jake Messier on Living with Metastatic Male Breast Cancer✨ | metastatic male breast cancerstigma+4 | Jake Messier | Oncology for the Inquisitive Mindwww.inquisitiveonc.com+2 | — | metastatic breast cancermale breast cancer+5 | Pfizer | 43m 58s | |
| 5/31/26 | ![]() 203. Back to Basics - Early Pancreatic Cancer✨ | pancreatic cancerneoadjuvant chemotherapy+4 | — | Oncology for the Inquisitive Mind | — | pancreatic cancerESPAC4+6 | Pfizer | 25m 30s | |
| 5/24/26 | ![]() 202. Back to Basics - Advanced Pancreatic Cancer✨ | advanced pancreatic cancertreatment options+5 | — | liposomal irinotecanNALIRIFOX+2 | — | pancreatic cancertreatment+5 | Pfizer | 22m 27s | |
| 5/17/26 | ![]() 201. Back to Basics - Advanced Gastric/GOJ Cancer✨ | advanced gastric cancerGOJ cancer+4 | — | trastuzumab deruxtecan | — | gastric cancerGOJ cancer+6 | Pfizer | 28m 21s | |
| 5/9/26 | ![]() 200. Back to Basics - Early Gastric Cancer✨ | gastric cancerimmunotherapy+3 | — | FLOT4-AIOMATTERHORN+1 | — | gastric cancerimmunotherapy+5 | Pfizer | 29m 01s | |
| 5/3/26 | ![]() 199. Back to Basics - Metastatic Colorectal Cancer - last line options✨ | metastatic colorectal cancertherapeutic options+5 | — | trifluridine-tipiracilLonsurf+2 | — | metastatic colorectal cancertrifluridine-tipiracil+6 | Pfizer | 23m 41s | |
| 4/26/26 | ![]() 198. Back to Basics - Early Oesophageal Cancer✨ | oesophageal cancerchemotherapy+3 | — | ESOPECCheckmate 577 | — | oesophageal cancerchemotherapy+5 | Pfizer | 27m 38s | |
| 4/18/26 | ![]() 197. Back to Basics - Metastatic Colorectal Cancer - HER2 positive disease and PI3K mutations✨ | Metastatic Colorectal CancerHER2 positive disease+4 | — | trastruzumab deruxtecan | — | metastatic colorectal cancerHER2+5 | Pfizer | 39m 04s | |
| 4/9/26 | ![]() 196. Back to Basics - Metastatic Colorectal Cancer - BRAFV600E and KRAS✨ | metastatic colorectal cancerBRAF mutations+4 | — | — | — | metastatic colorectal cancerBRAF mutations+6 | Pfizer | 26m 36s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 3/28/26 | ![]() 195. Back to Basics - Immunotherapy in Metastatic Colorectal Cancer✨ | immunotherapymetastatic colorectal cancer+3 | — | pembrolizumabipilimumab+1 | — | colorectal cancerimmunotherapy+6 | Pfizer | 25m 50s | |
| 3/21/26 | ![]() 194. Back to Basics - Metastatic Colorectal Cancer✨ | metastatic colorectal cancerchemotherapy+4 | — | cetuximabpanitumumab | — | metastatic colorectal cancerchemotherapy+6 | Pfizer | 26m 41s | |
| 3/14/26 | ![]() 193. Genitourinary Cancers and Prof Jonathan E Rosenberg MD✨ | genitourinary cancersmetastatic urothelial cancer+3 | Jonathan E. Rosenberg, MD | Memorial Sloan Kettering Cancer CentreWeill Cornell Medical College | — | urothelial cancerbladder cancer+3 | Pfizer | 37m 00s | |
| 3/7/26 | ![]() 192. Back to Basics - Early Colorectal Cancer - Part 2!✨ | colorectal cancerCTDNA+4 | — | ipilimumabnivolumab | — | colorectal cancerCTDNA+5 | Pfizer | 23m 30s | |
| 2/28/26 | ![]() 191. Back to Basics - Early Colorectal Cancer✨ | colorectal canceradjuvant regimen+3 | — | IDEASTransMET+1 | — | colorectal cancerFOLFOX+6 | Pfizer | 25m 48s | |
| 2/21/26 | ![]() 190. Back to Basics - Mesothelioma✨ | mesotheliomatreatment options+3 | — | MAPSCheckmate 743 | — | mesotheliomaipilimumab+5 | Pfizer | 18m 42s | |
| 2/16/26 | ![]() 189. Back to Basics - Extensive Stage Small Cell Lung Cancer✨ | extensive stage small cell lung cancernew treatments+3 | — | tarlatamablurbinectedin+2 | — | small cell lung cancertarlatamab+6 | Pfizer | 21m 18s | |
| 2/11/26 | ![]() 188. Gastrointestinal Cancer and Professor Jenny Seligmann | Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, is renowned for leading the groundbreaking FOxTROT and ARIEL trials. These studies challenged traditional practices by demonstrating the advantages of administering chemotherapy before surgery, a change now saving lives and influencing worldwide protocols. As a devoted mentor and a prominent participant in Cancer Research UK’s initiatives, she joins us to explore how we can personalise cancer treatment more effectively and discuss the future prospects for gastrointestinal cancer therapies. Welcome, Professor Seligmann.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 2/2/26 | ![]() 187. ESMO Awards - Episode 7 | In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium with an ARPI in advanced prostate cancer, whether de-escalation of docetaxel in high volume prostate cancer was just as efficacious as the regular six cycles, immunotherpay plus bCG in non-muscle invasive bladder cancer, adjuvant durvalumab in renal cell caricnoma and the perioperaive role of enforumab vedotin for muscle invasive bladder cancer.We're out of breath just listing off these trials, and if this hasn't gotten you excited, then probably nothing will! See you next week, where we interview our spectacular guest Professor Jenny Seligmann, who will bring you up to date on Michael's favourite topic, colorectal cancers!Studies:IMvigor011 (NCT04660344)KEYNOTE 905/EV-303 (NCT03924895)POTOMAC (NCT03528694)ARASAFE (NCT02799602)RC48-C016 (NCT05302284)PSMAddition (NCT04720157)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners, Pfizer and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 1/25/26 | ![]() 186. ESMO Awards - Episode 6 | ESMO Episode 6 is here! The longest award ceremony in the world continues. This episode covers colorectal cancer, a cancer stream that has relied heavily on the same three drugs for the past twenty-five years.We cover the golden pinnacle of real-world use cases for CTDNA, neoadjuvant immunotherapy in those with proficient MMR colorectal cancer, whether Zanzalimab helps in refractory colorectal cancer, and much more.Studies:BREAKWATERNEOADJUVANT IMMUNOTHERAPY (pMMR)STELLAR-303CHECKMATE 8HWFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 1/21/26 | ![]() 185. ESMO Awards - Episode 5 | We're back, baby! Michael and Josh predicted their ESMO journey would have eons to run, and they weren't wrong! For our first episode back in 2026, we revisit the important coverage of ESMO 2025, highlighting advances in upper gastrointestinal tract and hepatobiliary cancers. This episode covers FGFR inhibitors (Bemartizumab), updates on the MATTERHORN trial, the use of immunotherapy with trastuzumab and FLOT in HER2-positive localised oesophageal carcinoma, and investigates the use of TKIs and the novel drug nofazinlimab for those with unresectable or metastatic hepatocellular carcinoma.A jam-packed episode that aims to over-deliver on information, laughter, and hope.2026 is going to be a big one!Studies:FORTITUDE-101MATTERHORNPHERFLOT/IKF-053NCT04669496For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 12/13/25 | ![]() 184. ESMO Awards - Episode 4 | This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex immunotherapy targeting agent and the question of whether early discontinuation of immunotherapy could be beneficial.Studies:LITESPARK-15IMPRESS-Norway trialAbstract 1510M0BNT111 (NCT04526899)Safe Stop TrialFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 12/5/25 | ![]() 183. ESMO Awards - Episode 3 | For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer.Studies:DeLLphi-303SOHO-01ALBATROSPAULIENDREAM3ROptiTROP-Lung04For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 11/26/25 | ![]() 182. ESMO Awards - Episode 2 | ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.Studies:SOLTI-RIBOLARISPOSITIVEmonarchE:DESTINY-Breast11evERAASCENT-03TROPION-Breast02 trialROSELLADICE trialENGOT-ov65/KEYNOTE-B96 studyROSELLAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
| 11/15/25 | ![]() 182. ESMO Awards - Episode 1 | After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the inaugural Oncology for the Inquisitive Mind Awards. Today, they look at studies in pre-clinical science, supportive care and rare cancers to find their favourite studies amidst the goldmine that was this year's European Oncology Extravaganza.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information. | — | ||||||
Showing 25 of 223
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
6 placements across 6 markets.
Chart Positions
6 placements across 6 markets.




